Athenex ( ) - 株価, ニュースと分析OTCPK:ATNX.Q

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

ATNX.Q 株式概要

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer.

会社概要

ATNX.Q ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	0/6
配当金	0/6

報酬

リスク分析

意味のある時価総額がありません ( $132K )

マイナスの株主資本

過去3か月間の株価の変動は非常に激しい

過去5年間で収益は年間7.6%減少しました。

+1 さらなるリスク

Athenex, Inc. 競合他社

RegenETP

OTCPK:RGTP.Q

US$399.6k

Endonovo Therapeutics

OTCPK:ENDV

US$396.8k

Capstone Holding

OTCPK:CAPS

US$512.2k

SQZ Biotechnologies

OTCPK:SQZB

US$678.3k

価格と性能

の歴代最高値、変動、値下がりまとめAthenex
過去の株価
現在の株価	US$0.015
52週高値	US$6.00
52週安値	US$0.0003
ベータ	0.79
11ヶ月の変化	52.00%
3ヶ月変化	-86.19%
1年変化	-99.72%
33年間の変化	-99.99%
5年間の変化	-99.99%
IPOからの変化	-99.99%

Recent updates

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Mar 06

Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

Feb 19

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Jan 29

株主還元

	ATNX.Q	US Biotechs	US 市場
7D	0%	-0.1%	0.8%
1Y	-99.7%	21.7%	33.4%

業界別リターン: ATNX.Q過去 1 年間で8.4 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: ATNX.Qは、過去 1 年間で21.8 % のリターンを上げたUS市場を下回りました。

価格変動

Is ATNX.Q's price volatile compared to industry and market?
ATNX.Q volatility
ATNX.Q Average Weekly Movement	339.2%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.1%

安定した株価: ATNX.Qの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: ATNX.Qの週次ボラティリティは、過去 1 年間で167%から339%に増加しました。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2003	275	Johnson Lau	www.athenex.com

Athenex, Inc. 基礎のまとめ

Athenex の収益と売上を時価総額と比較するとどうか。
ATNX.Q 基礎統計学
時価総額	US$131.68k
収益（TTM）	-US$97.98m
売上高(TTM)	US$102.82m

0.0x

P/Sレシオ

0.0x

PER（株価収益率

ATNX.Q は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ATNX.Q 損益計算書（TTM）
収益	US$102.82m
売上原価	US$76.12m
売上総利益	US$26.70m
その他の費用	US$124.68m
収益	-US$97.98m

直近の収益報告

Dec 31, 2022

次回決算日

該当なし

一株当たり利益（EPS）	-11.31
グロス・マージン	25.97%
純利益率	-95.29%
有利子負債／自己資本比率	-511.7%

ATNX.Q の長期的なパフォーマンスは？

過去の実績と比較を見る

ATNX.Q 株式概要

報酬

リスク分析

Athenex, Inc. 競合他社

OTCPK:RGTP.Q

US$399.6k

OTCPK:ENDV

US$396.8k

OTCPK:CAPS

US$512.2k

OTCPK:SQZB

US$678.3k

価格と性能

最新ニュース

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Price target decreased to US$2.17

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Athenex prices $30M in stock and warrants offering

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex GAAP EPS, revenue misses estimates

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex to sell its China API business for $19M

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target decreased to US$4.50

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Price target decreased to US$4.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$5.50

Price target increased to US$6.67

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought US$61k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought US$161k worth of stock

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Consensus EPS estimates fall to -US$1.31

Price target decreased to US$7.50

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Independent Director exercised options to buy US$230k worth of stock.

Consensus EPS estimates increase to -US$1.42

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021